Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Gomes, Bruno; Driessens, Gregory; Bartlett, Derek; Cai, Danying; Cauwenberghs, Sandra; Crosignani, Stefano; Dalvie, Deepak; Denies, Sofie; Dillon, Christopher P.; Fantin, Valeria R.; Guo, Jie; Letellier, Marie-Claire; Li, Wenlin; Maegley, Karen; Marillier, Reece; Miller, Nichol; Pirson, Romain; Rabolli, Virginie; Ray, Chad; Streiner, Nicole

doi:10.1158/1535-7163.mct-17-1104

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Gomes, Bruno

;

Driessens, Gregory

;

Bartlett, Derek

;

Cai, Danying

;

Kraus, Manfred

;et.al.

(2018) Molecular Cancer Therapeutics — Vol. 17, n° 12, p. 2530-2542 (2018)

Files

No attached file found for this publication.

Details

Authors

Gomes, Bruno
Author
Driessens, Gregory
Author
Bartlett, Derek
Author
Cai, Danying
Author
Van den Eynde, BenoitUCLouvain
Author
Kraus, Manfred
Author

Affiliations

UCLouvainSSS/DDUV - Institut de Duve

Citations

APA
Chicago
FWB

Gomes, B., Driessens, G., Bartlett, D., Cai, D., Cauwenberghs, S., Crosignani, S., Dalvie, D., Denies, S., Dillon, C. P., Fantin, V. R., Guo, J., Letellier, M.-C., Li, W., Maegley, K., Marillier, R., Miller, N., Pirson, R., Rabolli, V., Ray, C., et al. (2018). Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy. Molecular Cancer Therapeutics, 17(12), 2530-2542. https://doi.org/10.1158/1535-7163.mct-17-1104 (Original work published 2018)